Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that principal investigator, Eva Feldman, MD, PhD, will give an update on NSI-566 Phase I and Phase II trial data in amyotrophic lateral sclerosis (ALS) at the American Neurological Association Annual Meeting in Chicago, Il on Monday, September 28, 2015.

Dr. Feldman will review the current state of cell-based therapies being studied for the treatment of neurological disorders, including Neuralstem’s NSI-566, an investigational spinal cord-derived stem cell therapy in development for ALS, in “The Current State of Stem Cell Therapies” session. The Phase I and II trials are the first in the world to use intraspinal stem cell transplantation. She will also discuss NSI-532.IGF, Neuralstem’s next-generation cell therapy for Alzheimer’s disease, at the meeting as part of the “Dementia and Aging” special interest group symposium. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and an unpaid consultant to Neuralstem.

Dr. Feldman will appear within the following ANA sessions:

Interactive Lunch Workshop: Current State of Stem Cell Therapies
Monday, September 28, 2015 – 11:45am to 1:00pm

Special Interest Group Symposia 3: Dementia and Aging
Monday, September 28, 2015 – 3:30pm to 5:30pm

  • Data Blitz Presentation featuring Dr. Feldman (5:20 – 5:30 pm):  Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer’s Disease (Original Source)

Shares of Neuralstem closed yesterday at $1.53. CUR has a 1-year high of $3.92 and a 1-year low of $1.25. The stock’s 50-day moving average is $1.45 and its 200-day moving average is $1.82.

On the ratings front, Neuralstem has been the subject of a number of recent research reports. In a report issued on August 10, Brean Murray Carret analyst Jonathan Aschoff maintained a Buy rating on CUR, with a price target of $8, which implies an upside of 422.9% from current levels. Separately, on June 29, MLV & Co.’s Ram Selvaraju reiterated a Buy rating on the stock and has a price target of $6.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Ram Selvaraju have a total average return of 5.2% and 6.2% respectively. Aschoff has a success rate of 45.8% and is ranked #593 out of 3766 analysts, while Selvaraju has a success rate of 43.4% and is ranked #689.

Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.